<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804568</url>
  </required_header>
  <id_info>
    <org_study_id>ALK3831-A104</org_study_id>
    <nct_id>NCT02804568</nct_id>
  </id_info>
  <brief_title>A Phase 1 Safety Study in Adults With Schizophrenia</brief_title>
  <official_title>A Multiple-dose, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALKS 3831 in Adult Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety, tolerability, and pharmacokinetics (PK) of olanzapine&#xD;
      and samidorphan in adults with schizophrenia following 14 consecutive days of oral&#xD;
      administration of ALKS 3831.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 15 days of dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration vs time curve over the 24 hour dosing interval (AUC0-24h)</measure>
    <time_frame>Up to 15 days of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be determined by incidence of drug-related adverse events</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine/samidorphan 10 mg/10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine/samidorphan 20 mg/10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 3831</intervention_name>
    <description>Oral capsule, daily administration</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a body mass index (BMI) of 18.0-35.0 kg/m^2, inclusive&#xD;
&#xD;
          -  Has a primary diagnosis of schizophrenia&#xD;
&#xD;
          -  Capable of understanding and complying with the procedures, requirements, and&#xD;
             restrictions of the protocol.&#xD;
&#xD;
          -  Appropriate for outpatient treatment&#xD;
&#xD;
          -  Agrees to abide by the contraception requirements specified in the protocol for the&#xD;
             duration of the study or is surgically sterile&#xD;
&#xD;
          -  Willing and able to provide government-issued identification&#xD;
&#xD;
          -  Is in good physical health&#xD;
&#xD;
          -  Agrees to maintain normal tobacco use as well as normal activities/exercise throughout&#xD;
             the study&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is currently pregnant or breastfeeding&#xD;
&#xD;
          -  Initiated first antipsychotic treatment within the past 12 months, or &lt;1 year has&#xD;
             elapsed since the initial onset of active-phase schizophrenia symptoms&#xD;
&#xD;
          -  Poses a current suicide risk at Visits 1 or 2&#xD;
&#xD;
          -  Has a history of poor or inadequate response to treatment with olanzapine&#xD;
&#xD;
          -  Has used a long-acting injectable antipsychotic medication in the last 6 months with&#xD;
             the exception of 3-month paliperidone, which must not have been received within the&#xD;
             past 12 months.&#xD;
&#xD;
          -  Requires or has had electroconvulsive therapy (ECT) treatment in the 6-month period&#xD;
             prior to Visit 1&#xD;
&#xD;
          -  Has a diagnosis of alcohol or drug use disorder (with the exception of nicotine)&#xD;
&#xD;
          -  Has taken opioid agonists (codeine, oxycodone, tramadol, or morphine) within the 14&#xD;
             days prior to Visit 1 and/or anticipates a need to take opioid medication during the&#xD;
             study period.&#xD;
&#xD;
          -  Has taken opioid antagonists including naltrexone (any formulations) and naloxone&#xD;
             within 60 days prior to Visit 1, or has used any extended-release formulation of an&#xD;
             opioid antagonist within 2 months prior to screening&#xD;
&#xD;
          -  Tests positive for amphetamines/methamphetamine, cocaine, barbiturates, opioids&#xD;
             (codeine, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and&#xD;
             buprenorphine), phencyclidine and benzodiazepines.&#xD;
&#xD;
          -  Has a known or suspected intolerance, allergy or hypersensitivity to olanzapine or&#xD;
             opioid antagonists.&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David McDonnell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Clementon</city>
        <state>New Jersey</state>
        <zip>08021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Alkermes</keyword>
  <keyword>ALK 3831</keyword>
  <keyword>Samidorphan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

